Skip to content

CorMedix up on FDA acceptance for filing and priority review of Defencath

August 31, 2020

FDA has accepted CorMedix (NYSEMKT:CRMD) +7% filing of new drug application for Defencath its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections.

The FDA had previously granted a rolling submission and review, which the Company completed at the end of June.

FDA also granted priority review and set a Prescription Drug User Fee Act date of February 28, 2021 for the completion of its review for approval of the NDA.

Source: Press Release

https://seekingalpha.com/news/3610072-cormedixplus-7-on-fda-acceptance-for-filing-and-priority-review-of-defencath

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: